Next Article in Journal
CTIFERK: A Thermal Infrared Facial Expression Recognition Model with Kolmogorov–Arnold Networks for Smart Classrooms
Previous Article in Journal
Homological Properties and Digital Relative Homology Groups of MA-Spaces
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Statistical Inference and Goodness-of-Fit Assessment Using the AAP-X Probability Framework with Symmetric and Asymmetric Properties: Applications to Medical and Reliability Data

by
Aadil Ahmad Mir
1,
A. A. Bhat
2,*,
S. P. Ahmad
1,
Badr S. Alnssyan
3,*,
Abdelaziz Alsubie
4 and
Yashpal Singh Raghav
5
1
Department of Statistics, University of Kashmir, Srinagar 190006, India
2
Department of Mathematical Sciences, Islamic University of Science and Technology, Awantipora 192122, India
3
Department of Management Information Systems, College of Business and Economics, Qassim University, Buraydah 51452, Saudi Arabia
4
Department of Basic Sciences, College of Science and Theoretical Studies, Saudi Electronic University, Riyadh 11673, Saudi Arabia
5
Department of Mathematics, College of Science, Jazan University, P.O. Box 2097, Jazan 45142, Saudi Arabia
*
Authors to whom correspondence should be addressed.
Symmetry 2025, 17(6), 863; https://doi.org/10.3390/sym17060863
Submission received: 14 April 2025 / Revised: 19 May 2025 / Accepted: 28 May 2025 / Published: 1 June 2025
(This article belongs to the Section Mathematics)

Abstract

Probability models are instrumental in a wide range of applications by being able to accurately model real-world data. Over time, numerous probability models have been developed and applied in practical scenarios. This study introduces the AAP-X family of distributions—a novel, flexible framework for continuous data analysis named after authors Aadil Ajaz and Parvaiz. The proposed family effectively accommodates both symmetric and asymmetric characteristics through its shape-controlling parameter, an essential feature for capturing diverse data patterns. A specific subclass of this family, termed the “AAP Exponential” (AAPEx) model is designed to address the inflexibility of classical exponential distributions by accommodating versatile hazard rate patterns, including increasing, decreasing and bathtub-shaped patterns. Several fundamental mathematical characteristics of the introduced family are derived. The model parameters are estimated using six frequentist estimation approaches, including maximum likelihood, Cramer–von Mises, maximum product of spacing, ordinary least squares, weighted least squares and Anderson–Darling estimation. Monte Carlo simulations demonstrate the finite-sample performance of these estimators, revealing that maximum likelihood estimation and maximum product of spacing estimation exhibit superior accuracy, with bias and mean squared error decreasing systematically as the sample sizes increases. The practical utility and symmetric–asymmetric adaptability of the AAPEx model are validated through five real-world applications, with special emphasis on cancer survival times, COVID-19 mortality rates and reliability data. The findings indicate that the AAPEx model outperforms established competitors based on goodness-of-fit metrics such as the Akaike Information Criteria (AIC), Schwartz Information Criteria (SIC), Akaike Information Criteria Corrected (AICC), Hannan–Quinn Information Criteria (HQIC), Anderson–Darling (A*) test statistic, Cramer–von Mises (W*) test statistic and the Kolmogorov–Smirnov (KS) test statistic and its associated p-value. These results highlight the relevance of symmetry in real-life data modeling and establish the AAPEx family as a powerful tool for analyzing complex data structures in public health, engineering and epidemiology.

1. Introduction

Probability models play a crucial role in statistical analysis, data modeling and real-world applications. However, no single probabilistic model can consistently outperform all others across diverse datasets and scenarios. This inherent limitation fuels ongoing research, inspiring statisticians to craft new probability distributions tailored to specific needs. Modifying or extending existing models often yields distributions that fit real-world data more closely than their predecessors. This drive for better fit, greater flexibility and wider applicability spans multiple disciplines and motivates continuous innovation.
One of the earliest and most fundamental methods for generating new distributions was introduced by Mudholkar and Srivastava [1], who crafted the Exponentiated Family of Distributions. Their elegant approach enhances a baseline distribution by adding a shape parameter—a simple twist that unlocks a broader spectrum of data patterns. It is an undeniable truth that no model reigns supreme; hence, statisticians tirelessly explore fresh models to capture reality’s complexities. The cumulative distribution function (CDF) of the exponentiated family is given by
F ( x ; γ , ζ ) = G ( x ; ζ ) γ , γ , ζ > 0 , x R .
Here, γ adds a new dimension of shape and G ( x ; ζ ) is the CDF of the base distribution, itself defined by ζ parameters. This elegant formulation breathes flexibility into classical distributions, molding them to suit intricate datasets.
Following this, Reference [2] introduced the Marshall–Olkin family of distributions. Their transformation reshapes the baseline CDF with an α parameter, yielding the following:
F ¯ M O ( α ; x ) = α F ¯ ( x ) 1 α ¯ F ¯ ( x ) ; α > 0 , α ¯ = 1 α , x R ,
where F ¯ ( x ) = 1 F ( x ) represents the survival function. This structure grants finer control over tail behavior, making it invaluable for reliability and risk analysis.
Building on this foundation, Reference [3] proposed the Alpha Power Transformation (APT), introducing a parameter ( α ) that redefines the baseline CDF ( G ( x ; β ) ) as follows:
F ( x ; α , ζ ) = α G ( x ; ζ ) 1 α 1 , α > 0 , α 1 G ( x ; β ) , α = 1 .
This transformation injects fresh flexibility, with the exponential distribution appearing as a special, illuminating case.
To further expand the toolkit, Reference [4] introduced the MIT transformation—named after its creators, Murtaza, Ishfaq and Tariq—enhancing a baseline CDF by weaving in a shape parameter ( α ):
F M I T ( x ; α ) = α F ( x ) 1 α ¯ F ( x ) ; α > 0 , α ¯ = 1 α , x R .
This simple yet powerful tweak opens doors to greater modeling flexibility.
Expanding horizons, Reference [5] applied the T-X family methodology by Reference [6] to create the New Exponent Power-X (NGEP-X) family, whose CDF reads as follows:
F ( x ; α , ζ ) = 1 e α G ( x ; ζ ) e α G ( x ; ζ ) , α > 0 , x R .
This formulation melds exponential power with a new perspective, enriching distribution shapes.
Meanwhile, Reference [7] unveiled the alpha-log-power transformed family (ALPTG), embedding a novel shape parameter independent of the parent model, offering fresh avenues for continuous distribution modeling:
F A L P T G ( x ) = α log 1 G ( x ; γ ) ,
Continuing the innovation, Reference [8] proposed the New Logarithmic Tangent-U (NLT-U) family, introducing the NLT-Wei model, a flexible Weibull-based sub-model. It showcases hazard functions that curve and twist—rising, falling, unimodal and bathtub-shaped functions—capturing real-world failure behaviors.
Riding the wave of novel approaches, Reference [9] embraced trigonometric transformations, crafting a family where the baseline distribution undergoes a sine- and cosine-inspired metamorphosis:
F ( x ; ζ ) = e 1 cos π G ( x ; ζ ) 1 + G ( x ; ζ ) 1 e 1 , ζ > 0 , x R .
This infusion of trigonometry injects rhythm into the shape of distributions, enhancing their expressive power.
Further enriching this path, Reference [10] introduced the ASP family, a sine-based flexible distribution that masterfully handles skewed and heavy-tailed data:
F ASP ( x ; α , ζ ) = 2 sin π 2 C ( x ; ζ ) α C ( x ; ζ ) α , α , ζ > 0 , x R .
This approach offers a robust alternative for engineering, medicine and beyond.
Finally, Reference [11] proposed the Alpha Beta Power-E (ABPE) Transformation, whose CDF is expressed as follows:
G ( z ) = α F ( z ) β F ( z ) α β , z R , α , β > 0 , α β 1 ,
bringing yet another harmonious blend of parameters to the family of flexible distributions.
In light of the extensive developments in probability distribution generation techniques discussed above, our study aims to contribute to this ongoing evolution by introducing a novel and more adaptable probability model. Many existing methods enhance baseline distributions by incorporating additional parameters, but these modifications can sometimes lead to re-parameterization issues, increased model complexity and challenges in practical implementation. To address these concerns, we propose an innovative AAP family of distributions, a flexible framework that refines existing distributions while minimizing the complexities associated with parameter inflation. The AAP-X family is designed to enhance the fitting ability of probability distributions, providing a more efficient and adaptable modeling approach. Unlike conventional transformation techniques that merely add parameters, the AAP-X method strategically modifies the structural properties of the base distribution to achieve greater flexibility without excessive parameterization. This innovative framework can effectively capture both symmetric and asymmetric data patterns through its shape-controlling mechanism, making it applicable across diverse domains.
As a specific application of our framework, we introduce an improved version of the exponential distribution using the AAP-X transformation. This enhanced model demonstrates superior flexibility, particularly in terms of its probability density function (PDF) and hazard rate function (HRF), allowing for a more accurate representation of real-life data. To validate its practical relevance and establish its superiority over classical models, we conducted a comparative analysis against several well-known models, including the Alpha Power Exponential and Marshall–Olkin Exponential models. These comparisons, presented in the application section of the manuscript, reveal that the AAP-X family consistently outperforms these traditional models based on standard goodness-of-fit criteria such as the AIC, BIC, AICC, HQIC and KS statistics.
Overall, this study not only introduces a novel statistical transformation but also preserves the theoretical elegance while addressing practical challenges. Its ability to capture diverse data behaviors, particularly symmetry and asymmetry, makes it highly relevant for applications in reliability analysis, survival studies, epidemiology and beyond.
The remainder of this paper is structured as follows: Section 2 presents the research gap and highlights the need for developing the proposed AAP-X family of distributions. Section 3 introduces the proposed AAP-X family of distributions, along with its mathematical formulation and key properties. Section 4 presents a special case of the family based on the exponential distribution, which serves as a tractable and insightful example. It also discusses various structural characteristics of the model, including the hazard rate function, moments and the moment-generating function. In Section 5, estimation of parameters is addressed using six methods of estimation. Section 6 includes a detailed simulation study to compare the performance of estimators. In Section 7, the practical utility of the model is demonstrated through real-world data applications. Finally, Section 8 concludes the paper with a summary of findings and directions for future research.

2. Research Gap

The existing literature on extended distributions, particularly those enhancing baseline models such as the exponential distribution, reveals several limitations and gaps that warrant further investigation. This paper aims to address the following specific research gaps:
  • Existing transformation techniques often increase model complexity through additional parameters, leading to parameter inflation without substantial gains in flexibility.
  • Several extended models fail to offer adequate flexibility in capturing both symmetric and asymmetric data patterns observed in real-world datasets.
  • There has been limited exploration of transformation frameworks that preserve theoretical tractability while enhancing distributional shapes.
  • Many proposed models do not comprehensively evaluate estimation techniques, resulting in limited insights into their practical implementation.
  • Prior works do not offer extensive empirical comparisons across diverse real-life datasets, especially from both medical and engineering domains.
  • Limited research exists to assess the performance of new distributions using a wide range of goodness-of-fit criteria and graphical diagnostics.
  • The integration of domain-specific datasets for validation of new models remains underexplored, especially in the context of survival and reliability data.
This study responds to the above research gaps by proposing the AAP-X family of distributions, which enhances model flexibility without excessive parameterization and is validated using extensive real-world applications and simulation-based performance comparisons.

3. The Model and Properties

In this section, we introduce a novel family of probability distributions, termed the Aadil Ajaz–Parvaiz-X (AAP-X) Family. The primary motivation behind the development of this family is to enhance the flexibility of existing probability models by incorporating an additional parameter that adjusts the shape and scale properties of the baseline distribution. This transformation aims to provide better modeling capabilities for complex real-world data structures across various disciplines, including engineering, finance and survival analysis. The AAP-X family is defined by modifying the cumulative distribution function (CDF) of a baseline distribution ( G ( x ; ζ ) , where ζ represents the parameter vector of the base distribution). The transformation introduces a new shape control parameter ( α ) that governs the behavior of the tail and the adaptability of the resulting distribution. To understand the behavior and practical utility of the AAP-X family, we explore key statistical properties.
Definition 1. 
Let G ( x ; ζ ) represent the CDF of the reference model. Then, the CDF ( F ( x ; γ , ζ ) ) of the AAP-X family, incorporating the additional shape parameter (γ), is obtained as follows:
F ( x ; γ , ζ ) = α [ G ( x ; ζ ) ] γ 1 α ¯ [ G ( x ; ζ ) ] γ ; α , γ , ζ , R + , x R , α ¯ = 1 α .
To aid in the understanding of the transformation process from the baseline distribution to the proposed AAP-X family, a schematic flow diagram is presented in Figure 1. This flowchart visually summarizes the key steps involved in deriving the cumulative distribution function (CDF) of the AAP-X family.
It is straightforward to verify that the cumulative distribution function (CDF) defined in Equation (10) satisfies the essential properties of a valid distribution function. Specifically, the following holds:
lim x F ( x ; γ , ζ ) = 0 and lim x F ( x ; γ , ζ ) = 1 ,
and the function is right-continuous and differentiable. Hence, the expression in Equation (10) is a valid CDF. The probability density function (PDF) corresponding to the CDF in Equation (10) is given by Equation (11):
f ( x ; γ , ζ ) = α γ g ( x ; ζ ) G ( x ; ζ ) γ 1 1 α ¯ G ( x ; ζ ) γ 2 , α , γ , ζ R + , x R , α ¯ = 1 α .
Here, g ( x ; ζ ) = d d x G ( x ; ζ ) is the PDF of the baseline distribution, and G ( x ; ζ ) is its CDF.
Mathematically, the AAP-X family generalizes several well-established transformation techniques. Its flexibility is illustrated through the following special cases:
  • When γ = 1 , Equation (10) reduces to Equation (4), representing the MIT technique proposed in Reference [4].
  • When α = 1 , Equation (10) simplifies to Equation (1), which corresponds to the exponentiated transformation technique proposed in Reference [1].
  • When γ = 1 and α = 1 , Equation (10) collapses to F ( x ) , the CDF of the baseline distribution.
These reductions confirm that the proposed AAP technique not only generalizes existing transformation approaches but also unifies them under a common framework. Such unification enables a comprehensive exploration of the effects of transformation parameters on the distributional shape, skewness and tail behavior.

3.1. Aging Properties

The term “aging properties” in statistical modeling and survival analysis refers to features of a survival distribution that characterize the evolution of the probability of failure or death. These properties are important in understanding the lifetime behavior and dependability of systems or individuals. For the proposed AAP-X family, the survival function (SF), hazard rate (HR) and cumulative hazard function (CHF) measures are calculated as follows:
S ( x ; ζ ) = 1 [ G ( x ; ζ ) ] γ 1 α ¯ [ G ( x ; ζ ) ] γ .
h ( x ; ζ ) = α γ g ( x ; ζ ) [ G ( x ; ζ ) ] γ 1 1 α ¯ [ G ( x ; ζ ) ] γ ] 1 [ G ( x ; ζ ) ] γ .
H ( x ; ζ ) = l n 1 [ G ( x ; ζ ) ] γ 1 α ¯ [ G ( x ; ζ ) ] γ .

3.2. Quantile Function

The quantile function is an important tool in many statistical methods, including Monte Carlo techniques. By inverting the CDF of a distribution, it is possible to extract random numbers from that distribution. Given a random variable (X) that belongs to the AAP-X family, the quantile function for X can be found in the manner described below:
F ( x ; ζ ) = α [ G ( x ; ζ ) ] γ 1 α ¯ G ( x ; ζ ) ] γ = u ; 0 < u < 1 .
Solving for G ( x ; ζ ) , we obtain
G ( x ; ζ ) = u α + α ¯ u 1 γ
In order to determine the quantile function ( Q X ( u ) ) for the AAP-X family, we need the inversion function of G ( x ; ζ ) . Thus,
Q X ( u ) = G 1 u α + α ¯ u 1 γ
Therefore, by applying Equation (17) for a specific baseline CDF-G, random variates from the AAP family can be generated.

3.3. Moments and Moment-Generating Function

For the AAP-X family introduced in this study, the ordinary rth moment is calculated as
μ r = Ω x r f ( x ; γ , ζ ) d x = Ω x r α γ g ( x ; ζ ) G ( x ; ζ ) γ 1 1 α ¯ G ( x ; ζ ) γ 2 d x .
using the following series representation:
( 1 x ) 2 = a = 0 ( a + 1 ) x a ; | u | < 1 ,
μ r = α γ k = 0 ( k + 1 ) α ¯ k Ω x r G ( x ; ζ ) γ ( k + 1 ) 1 g ( x ; ζ ) d x , = α γ k = 0 ( k + 1 ) α ¯ k λ 1 , i ( x ; ζ ) .
where
λ 1 , i ( x ; ζ ) = Ω x r G ( x ; ζ ) γ ( k + 1 ) 1 g ( x ; ζ ) d x .
Moreover, the MGF, denoted as M x ( t ) for an AAP-X distributed random variable (X), is obtained as follows:
M x ( t ) = Ω ( t x ) r r ! f ( x ; γ , ζ ) d x , = α γ r , k = 0 t r r ! ( k + 1 ) α ¯ k λ 1 , i ( x ; ζ ) .

3.4. Order Statistics

In distribution theory, order statistics (OS) are essential because they characterize the operational time of systems, and components and are crucial to reliability analysis, estimate theory and life testing. Consider a random sample of observations ( X 1 , X 2 , X 3 , , X n ) drawn from the AAP-X family with a CDF and PDF provided by Equations (10) and (11). The PDF of the rth order statistics—say, X r : n —is then calculated as follows:
f r : n ( x ; γ , ζ ) = 1 B ( r , n r + 1 ) f ( x ; γ , ζ ) F ( x ; γ , ζ ) r 1 1 F ( x ; γ , ζ ) n r ,
The expansion of 1 F ( x ; γ , ζ ) n r in binomial form is provided as follows:
1 F ( x ; γ , ζ ) n r = k = 0 n r n r k ( 1 ) k F ( x ; γ , ζ ) k ,
By substituting Equation (21) in Equation (20), we derive
f r : n ( x ; α , ζ ) = 1 B ( r , n r + 1 ) f ( x ; α , ζ ) k = 0 n r n r k ( 1 ) k F ( x ; α , ζ ) r + k 1 .
Replacing Equations (10) and (11) in Equation (22) yields the PDF of the X r : n statistics.

3.5. Residual and Reverse Residual Lifetime

The notions of residual lifetime (RL) and reverse residual lifetime (RRL) are widely applicable in several fields, including survival modeling, actuarial science, biometrics and risk assessment. Within the framework of the AAP-X family, the RL of a random variable (X), represented as R X ( t ) , is described as follows:
R X ( t ) = S ( x + t ) S ( t ) , = ( 1 [ G ( x + t ; ζ ) ] γ ) ( 1 α ¯ [ G ( t ; ζ ) ] γ ) ( 1 [ G ( t ; ζ ) ] γ ) ( 1 α ¯ [ G ( x + t ; ζ ) ] γ ) .
In addition, we also derive the expression for the RRL of a random variable (X) following the AAP-X family. The calculated expression denoted as R X ¯ ( t ) is defined as
R X ¯ ( t ) = S ( x t ) S ( t ) , = ( 1 [ G ( x t ; ζ ) ] γ ) ( 1 α ¯ [ G ( t ; ζ ) ] γ ) ( 1 [ G ( t ; ζ ) ] γ ) ( 1 α ¯ [ G ( x t ; ζ ) ] γ ) .

4. Special Case

In this part, we present a specific case within the AAP-X family by extending the exponential distribution.

4.1. AAP Exponential (AAPEx) Distribution

In this subsection of the article, a particular subclass of the AAP-X family, characterized by three parameters is introduced. We refer to this particular model as the AAP Exponential (AAPEx) model. The CDF ( G ( x ; η ) ) and PDF ( g ( x ; η ) ) of the exponential distribution are defined as follows:
G ( x ; η ) = 1 e η x ; x 0 , η > 0 ,
and
g ( x ; η ) = η e η x .
By inserting Equations (23) and (24) into Equations (10) and (11), we get the updated version of the exponential distribution (i.e., AAPEx) model as expressed by
F ( x ; α , γ , η ) = α ( 1 e η x ) γ 1 α ¯ ( 1 e η x ) γ ; α , γ , η > 0 , x > 0 , α ¯ = 1 α ,
and the PDF takes the form as
f ( x ; α , γ , η ) = α γ η e η x ( 1 e η x ) γ 1 [ 1 α ¯ ( 1 e η x ) γ ] 2 .
In order to enhance reader understanding, we provide the following clear explanations for the roles of each parameter in the proposed AAPEx model:
  • The shape and tail behaviors are largely controlled by the α parameter. It improves the flexibility of the model by modifying the weight of the modified function.
  • The steepness of the cumulative distribution function is influenced by the γ parameter. It influences the skewness and kurtosis, making the model capable of capturing asymmetric patterns in data.
  • The η parameter is the scale parameter from the baseline exponential distribution. It affects the spread of distribution by controlling the rate of decay.
  • For the transformation to stay valid and the resultant function to remain a suitable CDF, the formula expressed as α ¯ = 1 α is utilized.
The statistical properties, including SF ( S ( x ; α , γ , η ) ), HF ( h ( x ; α , γ , η ) ) and CHF ( H ( x ; α , γ , η ) ) for the special sub-model, are derived as follows:
S ( x ; α , γ , η ) = 1 ( 1 e η x ) γ 1 α ¯ ( 1 e η x ) γ .
h ( x ; α , γ , η ) = α γ η e η x 1 e η x γ 1 1 α ¯ 1 e η x γ 1 1 e η x γ .
and
H ( x ; α , γ , η ) = l n 1 ( 1 e η x ) γ 1 α ¯ ( 1 e η x ) γ .
In addition, for the QF of X, the AAPEx model is expressed as follows:
X u = l n 1 u α + α ¯ u 1 γ 1 η ; 0 < u < 1 .
Specifically, u = 0.5 , 0.25 and 0.75 are used in Equation (30) to determine the quartiles, Bowley’s skewness and Moor’skurtosis of the AAPEx model, respectively (see Table 1).
Figure 2 illustrates the PDF curves of the AAPEx model for different settings of the α , γ and η parameters. The plots demonstrate a wide variety of shapes, such as unimodal right-skewed (for α = 0.25 , γ = 1.5 and η = 3.75 ), J-shaped or strictly increasing (for α = 0.7 , γ = 6.5 and η = 0.05 ), and L-shaped or right-skewed (for α = 1.5 , γ = 1.5 and η = 2.5 ). Additionally, a bimodal and asymmetrical shape is observed when α = 0.15 , γ = 0.8 and η = 1.5 , while a left-skewed unimodal form arises for α = 0.4 , γ = 2.5 and η = 3 . A monotonically decreasing or exponential-type decay is evident for α = 0.9 , γ = 1 and η = 3 . These variations highlight the flexibility of the AAPEx model in representing both symmetric and asymmetric distributions, making it a suitable choice for modeling real-world lifetime data.
Figure 3 illustrates the hazard rate function (hrf) of the AAPEx model for various combinations of the α , γ and η parameters and demonstrates its ability to exhibit a wide range of asymmetrical forms. The plots reveal a rich variety of shapes. An increasing hazard rate is observed for ( α = 0.7 , γ = 6.5 , η = 0.05 ) , while a bathtub-shaped curve appears for ( α = 0.15 , γ = 0.5 , η = 2.5 ) . An upside-down bathtub shape is evident in the case of ( α = 0.15 , γ = 0.3 , η = 2.9 ) , and a decreasing hazard rate is shown for ( α = 1.5 , γ = 1.5 , η = 0.9 ) . Additionally, a reversed J-shaped hrfis observed for ( α = 0.9 , γ = 1 , η = 3 ) . These distinct forms highlight the flexibility of the AAPED model in capturing various lifetime behaviors and support its applicability to a broad spectrum of real-world reliability data.

4.2. Moments and Moment-Generating Function

The r th moment can be calculated by substituting Equations (25) and (26) into Equation (18), which yields
μ r = α η γ k = 0 ( k + 1 ) α ¯ k 0 x r 1 e η x γ ( k + 1 ) 1 e η x d x .
Using series expansion, we obtain the following:
( 1 x ) n = p = 0 ( 1 ) p n p x p
μ r = α γ η k , p = 0 ( 1 ) p ( k + 1 ) γ 1 p ( k + 1 ) α ¯ k 0 x r e ( p + 1 ) η x d x .
Thus, the rth moment for AAPEx model is given as
E ( X r ) = α γ η k , p = 0 ( 1 ) p ( k + 1 ) γ 1 p ( k + 1 ) α ¯ k Γ r + 1 ( p + 1 ) η r + 1 .
Using the series representation of e t x , we have
M X ( t ) = r = 0 t r r ! E ( X r )
Substituting the value of Equation (34) into Equation (35), we get the moment-generating function of the AAPEx model as follows:
M X ( t ) = α γ η r , k , p = 0 t r r ! ( 1 ) p ( k + 1 ) γ 1 p ( k + 1 ) α ¯ k Γ r + 1 ( p + 1 ) η r + 1
Table 1 provides a detailed computation of three key statistical measures—quantiles, Bowley skewness and Moor’s kurtosis—across a range of parameter combinations.

5. Parameter Estimation

In this section, we explore the estimation of the parameters of the AAPEx model through various frequentist estimation methods. Parameter estimation serves as a fundamental step for applied statisticians and reliability engineers, offering a structured approach to identify the most appropriate estimation technique for the model. Six estimation techniques are considered for the AAPEx model parameters, namely maximum likelihood estimation ( Δ 1 ), Cramér–von Mises estimation ( Δ 2 ), maximum product of spacings estimation ( Δ 3 ), ordinary least squares estimation ( Δ 4 ), weighted least squares estimation ( Δ 5 ) and Anderson–Darling estimation ( Δ 6 ).

5.1. Maximum Likelihood Estimation ( Δ 1 ) for a Complete Sample

Let random variables X 1 , X 2 , , X n be a random sample whose observed values ( x 1 , x 2 , , x n ) are from the AAPEx model with the PDF ( f ( x ; α , γ , η ) ) given in Equation (26). The likelihood function corresponding to f ( x ; α , γ , η ) —say, L ( α , γ , η ) —is given as
L ( α , γ , η ) = k = 1 n f ( x k ; α , γ , η )
Taking the natural logarithm of the likelihood function, the log-likelihood function ( ( α , γ , η ) ) is given by
( α , γ , η ) = k = 1 n log f ( x k ; α , γ , η )
Substituting the PDF of the AAPEx model, i.e.,
f ( x ; α , γ , η ) = α γ η e η x ( 1 e η x ) γ 1 1 ( 1 α ) ( 1 e η x ) γ 2 ,
we get
( α , γ , η ) = n log ( α γ η ) η k = 1 n x k + ( γ 1 ) k = 1 n log ( 1 e η x k ) 2 k = 1 n log 1 ( 1 α ) ( 1 e η x k ) γ
The derivatives of ( α , γ , η ) with respect to α , γ and η are delineated as
α ( α , γ , η ) = n α 2 k = 1 n ( 1 e η x k ) γ ( 1 α ¯ ( 1 e η x k ) γ ) .
and
γ ( α , γ , η ) = n γ + k = 1 n l n ( 1 e η x k ) 2 α ¯ k = 1 n ( 1 e η x k ) γ l n ( 1 e η x k ) ( 1 α ¯ ( 1 e η x k ) γ ) .
η ( α , γ , η ) = n η + ( γ 1 ) k = 1 n x k e η x k ( 1 e η x k ) k = 1 n x k + 2 α ¯ k = 1 n x k e η x k ( 1 e η x k ) γ 1 ( 1 α ¯ ( 1 e η x k ) γ ) .
By evaluating the system of non-linear equations ( α ( α , γ , η ) = 0 , γ ( α , γ , η ) = 0 and η ( α , γ , η ) = 0 ), the maximum likelihood estimates for the parameters of the AAPEx model can be obtained.

5.2. Cramer-von Mises Estimation (CVME)( Δ 2 )

The CVME parameter estimation technique is also a powerful tool for parameter estimation. By minimizing the CVM statistic, the method provides parameter estimates that optimize the fit between the observed data and the expected distribution.
C ( α , γ , η ) = 1 12 n + k = 1 n F ( x ( k ) ) 2 k 1 2 n 2 , = 1 12 n + k = 1 n + 1 α ( 1 e η x ( k ) ) γ 1 α ¯ ( 1 e η x ( k ) ) γ 2 k 1 2 n 2 .
By evaluating the system of non-linear equations ( α C ( α , γ , η ) = 0 , γ C ( α , γ , η ) = 0 and η C ( α , γ , η ) = 0 ), we procure the Cramer-von Mises estimates for the parameters of the AAPEx model.

5.3. Maximum Product of Spacing Estimation (MPSE) ( Δ 3 )

The MPS method is a parameter estimation technique used to fit probability distributions to data. It maximizes the product of the spacings (gaps) between ordered data points in the CDF. It provides robust parameter estimates by focusing on the spacing of data points rather than their exact values.
D k = F ( x ( k ) ) F ( x ( k 1 ) ) ; k = 1 , 2 , , n + 1
where F ( x ( 0 ) ) = 0 and F ( x ( n ) ) = 1 . The maximum product of spacing estimators is obtained by maximizing the following function:
M ( α , γ , η ) = 1 n + 1 k = 1 n + 1 l n [ D k ] = 1 n + 1 k = 1 n + 1 l n α ( 1 e η x ( k ) ) γ 1 α ¯ ( 1 e η x ( k ) ) γ α ( 1 e η x ( k 1 ) ) γ 1 α ¯ ( 1 e η x ( k 1 ) ) γ .
By solving the non-linear equations ( α M ( α , γ , η ) = 0 , γ M ( α , γ , η ) = 0 and η M ( α , γ , η ) = 0 ), we procure the maximum product of spacing estimates for the parameters of the AAPEx distribution.

5.4. Ordinary Least Squares Estimation (LSE) ( Δ 4 ) and Weighted Least Squares Estimation (WLSE) ( Δ 5 )

LSE is a widely used method for estimating the parameters of a model by minimizing the sum of the squared differences (errors) between observed data and the values predicted by the model.
S ( α , γ , η ) = k = 1 n F ( x ( k ) ) k n + 1 2 = k = 1 n + 1 α ( 1 e η x ( k ) ) γ 1 α ¯ ( 1 e η x ( k ) ) γ k n + 1 2 .
Similarly, WLS generalizes OLS by assigning weights to each data point, giving more importance to observations with lower variance or higher reliability.
W ( α , γ , η ) = k = 1 n ( n + 1 ) 2 ( n + 2 ) k ( n k + 1 ) F ( x ( k ) ) k n + 1 2 = k = 1 n ( n + 1 ) 2 ( n + 2 ) k ( n k + 1 ) α ( 1 e η x ( k ) ) γ 1 α ¯ ( 1 e η x ( k ) ) γ k n + 1 2 .

5.5. Anderson–Darling Estimation (ADE) ( Δ 6 )

The ADE parameter estimation technique is a powerful tool for fitting models to data, particularly when sensitivity to the tails of the distribution is important. By minimizing the AD statistic, the method provides parameter estimates that optimize the fit between the observed data and the hypothesized distribution.
A ( α , γ , η ) = n 1 n k = 1 n ( 2 k 1 ) l n F ( x ( k ) ) + l n S ( x ( n + 1 k ) ) = n 1 n k = 1 n ( 2 k 1 ) l n α ( 1 e η x ( k ) ) γ 1 α ¯ ( 1 e η x ( k ) ) γ + l n 1 ( 1 e η x ( n + 1 k ) ) γ 1 α ¯ ( 1 e η x ( n + 1 k ) ) γ .
By evaluating the non-linear equations ( α A ( α , γ , η ) = 0 , γ A ( α , γ , η ) = 0 and η A ( α , γ , η ) = 0 ), we obtain the Anderson–Darling estimates of the parameters of the proposed distribution.

6. Simulation Illustration

Here, we perform an extensive Monte Carlo simulation study to systematically evaluate the performance of several estimation strategies used for the suggested probability distribution. The main motivation of this simulation is to compare and investigate the performance of each estimator based on its accuracy, efficiency and robustness under different sample sizes and situations. Each sample is analyzed with six estimation procedures: MLE, CVME, MPSE, OLSE, WLSE and ADE. For comparison of these estimation methods, we evaluate the absolute bias (AB), mean relative estimate (MRE) and mean squared error (MSE) for each estimate. The following equations are employed to generate the statistics:
AB = 1 n i = 1 n ( θ ^ i θ i ) ,
MSE = 1 n i = 1 n ( θ ^ i θ i ) 2 ,
and
MRE = 1 n i = 1 n θ ^ i θ i θ i .
We perform exhaustive simulation analysis with many iterations in order to accomplish this. Random samples of the sizes n = 25 , 50 , 100 , 150 , 250 and 400 are simulated from our proposed model based on three different sets of parameter values, as shown below.
  • S e t I : α = 0.25 , γ = 0.15 and η = 0.35 ,
  • S e t I I : α = 0.7 , γ = 2.0 and η = 0.8 ,
  • S e t I I I : α = 1.2 , γ = 0.7 and η = 2.1 .
The results of the simulation analysis are reported in Table 2, Table 3 and Table 4. By reviewing these tables together, we can compare the relative strengths and efficiency of the various estimation approaches studied in this research. The obtained findings play a crucial role in determining the most appropriate estimation method for subsequent applications and research studies.
A number of inferences can be made from the systematic examination of the simulation findings, such as the following:
  • The bias of every estimator, regardless of the estimation technique, decreases as the sample size increases. This suggests that larger samples produce estimates that are more accurate and have less systematic error.
  • The mean squared error (MSE) for any method of estimation decreases with a larger sample size. This means increased precision in the estimates resulting from a decrease in variance, as well as bias with larger samples.
  • Similarly, for all estimators, the mean relative error (MRE) decreases with increasing sample size, demonstrating that larger samples minimize relative errors and yield more accurate and exact estimates.
  • Regardless of sample size, the MLE and MPS approaches consistently exhibit the lowest bias, MSE and MRE, demonstrating their superior dependability for parameter estimation. These techniques have low errors across sample sizes and are very effective.
  • In comparison to MLE and MPS, the CVM approach consistently has higher bias, MSE and MRE, despite showing some improvement with bigger sample numbers. Therefore, CVM is not as accurate or efficient as MLE or MPS, even if it might improve with larger samples.
  • Particularly for smaller sample sizes, the OLS and WLS approaches typically have the highest bias, MSE and MRE. This indicates that these techniques may not be as appropriate for high-quality estimation in any situation because of their lower accuracy and precision when compared to MLE and MPS.

7. Applications in Medical Research and Engineering

In this section, the flexibility and efficiency of the AAPEx distribution are assessed by comparing its performance across real-world datasets from both medical and engineering domains, with particular emphasis on cancer survival, COVID-19 mortality and reliability data. Distributions considered in this study are the Exponential (Ex) distribution of Reference [12], the Exponentiated Exponential (EEx) distribution of Reference [13], the Weibull (W) distribution, the Sine Exponential (SEx) distribution of Reference [14], the Gamma (G) distribution, the Alpha Power Exponential (APEx) distribution of Reference [15], the Kumaraswamy Exponential (KwEx) distribution by Reference [16] and the Marshal–Olkin Exponential (MoEx) distribution of Reference [2]. For the purposes of comparison, multiple goodness-of-fit (GoF) measures are evaluated, including the Akaike Information Criteria (AIC), Schwartz Information Criteria (SIC), Akaike Information Criteria Corrected (AICC), Hannan–Quinn Information Criteria (HQIC), Anderson–Darling (A*) test statistic, Cramer-von Mises (W*) test statistic, and the Kolmogorov–Smirnov (KS) test statistic and its associated p-value. The optimal distribution has lower values for all GoF metrics, except for the p-value, which must be higher.
For clarity and completeness, the analytical expressions of the probability density functions (PDFs) of the competing models are presented below:
  • The exponential (Ex) distribution with a PDF is expressed as
    g ( x ; η ) = η e η x ; η R + .
  • The exponentiated exponential (EEx) distribution with a PDF is expressed as
    g ( x ; α , η ) = α η e η x ( 1 e η x ) α 1 ; α , η R + .
  • The Weibull (W) distribution with a PDF is expressed as
    g ( x ; α , η ) = α η x η α 1 exp x η α ; α , η R + .
  • The sine exponential (SEx) distribution with a PDF is expressed as
    g ( x ; η ) = π 2 β e η x cos π 2 1 e η x ; η R + .
  • The Gamma (G) distribution with PDF as:
    f ( x ; α , η ) = η α x α 1 e η x Γ ( α ) for x 0 , k > 0 , λ > 0
  • The alpha power exponential (APEx) distribution with a PDF is expressed as
    g ( x ; α , η ) = η log ( α ) α 1 e η x α 1 e η x ; α , η R + .
  • The Kumaraswamy exponential (KwEx) distribution with a PDF is expressed as
    g ( x ; a , b , β ) = α γ η e η x 1 e η x a 1 1 1 e η x α γ 1 ; α , γ , η R + .
  • The Marshal–Olkin exponential (MoEx) distribution with a PDF is expressed as
    g ( x ; a , b , β ) = α γ η e η x 1 e η x a 1 1 1 e η x α γ 1 ; α , γ , η R + .

7.1. Application 1: Survival Time of 44 Head and Neck Cancer Patients

The first application analyzes the survival times of 45 patients diagnosed with head and neck cancer. The dataset was retrieved from Reference [17]. This real-world medical dataset, as detailed in [18], follows a progressive Type-I censoring scheme and involves patients treated with a combination of radiation and chemotherapy. The data is positively skewed, highlighting the presence of extreme survival times. The complete dataset is included in Appendix A.
Table 5 consists of the summary statistics for the survival times of 45 patients diagnosed with head and neck cancer disease. The data is extremely positively skewed, as the skewness value is greater than 1. The kurtosis value is greater than 3, indicating that the dataset is leptokurtic.
The failure rate of application 1 is bathtub-shaped because the TTT-transform plot displayed in Figure 4 is initially convex below the 45 line, then concave above the 45 line, and the boxplot has few outliers, as in shown in Figure 4.
The maximum likelihood estimates (MLEs) and the GoF statistics, along with the corresponding p-values of the application described in Section 7.1 for the fitted models, including the AAPEx distribution and other competing distributions, are presented in Table 6. The negative logarithm and the information criteria are reported in Table 7. The results show that the AAPEx distribution has the smallest values of A*, W* and K-S, along with the largest p-value. This confirms that it provides a superior fit to the survival data compared to other models evaluated in the study.

7.2. Application 2: Remission Times of 36 Bladder Cancer Patients

The second application represents the remission times (in months) for 36 patients diagnosed with bladder cancer, as already analyzed by Reference [19]. The dataset is fully observed, meaning that all remission times are complete, with no censored or truncated observations. No pre-processing was required beyond basic sorting and validation to ensure consistency with the original source. The observations of the dataset are reported in Appendix A.
The summary statistics of the remission times of 36 bladder cancer patients are provided in Table 8. The dataset is negatively skewed, as the skewness value is less than 0. The kurtosis value is less than 3, indicating that the dataset is platykurtic.
The maximum likelihood estimates (MLEs) and the GoF statistics, along with the corresponding p-values of the application described in Section 7.2 for the fitted models, including the AAPEx distribution and other competing distributions, are presented in Table 9. The negative logarithm and the information criteria are reported in Table 10. The results show that the AAPEx distribution has the smallest values of A*, W* and K-S, along with the largest p-value. This confirms that it provides a superior fit to the bladder cancer data compared to other models evaluated in this study.
The TTT-transform plot of the data shows a concave pattern above the 45° line, providing insight into the shape of the hazard function, as shown in Figure 3, and no outlier is revealed in the boxplot illustrated in Figure 5.

7.3. Application 3: Remission Times of 128 Bladder Cancer Patients

The third application, comprising uncensored remission times (in months) for 128 patients diagnosed with bladder cancer, exhibits a pronounced right-skewed distribution, as discussed by Reference [20]. The remission times are presented in Appendix A.
The summary statistics of the remission times of 128 bladder cancer patients are provided in Table 11. The dataset is positively skewed and leptokurtic (skewness = 3.32 and kurtosis = 16.15).
The maximum likelihood estimates (MLEs) and the GoF statistics with respective p-values of the application described Section 7.3 are exhibited in Table 12. The information criteria and negative logarithm are provided in Table 13. All results indicate that the proposed model possesses the smallest A*, W* and K-S values, in addition to having the largest p-value. This attests to the fact that it offers the best fit of the bladder cancer data among models assessed in this study.
The TTT plot of Dataset 3 is S-shaped—first convex below the 45 line, then concave above it. This suggests a bathtub-shaped hazard rate, with decreasing, constant, then increasing failure rates over time, as shown in Figure 6.

7.4. Application 4: United Kingdom COVID-19 Mortality Rate Data

The fourth real-life application involves a dataset comprising COVID-19 mortality rates in the United Kingdom. This dataset was previously utilized by References [21,22]. The data were originally retrieved from the World Health Organization (WHO) COVID-19 [https://covid19.who.int/], which provides official global statistics on COVID-19 cases and deaths. The dataset is fully observed, with no censored or truncated values, and each observation represents a recorded mortality rate at a specific time point. Prior to analysis, basic preprocessing steps such as sorting and validation against the WHO database were performed to ensure consistency and accuracy.
Table 14 reports the summary statistics of the UK COVID-19 death rate data. The positive skewness means that the dataset is skewed to the right, and the kurtosis of less than 3 implies that it is platykurtic. The failure rate is of a bathtub shape, since the TTT-transform plot is first convex (below the 45° line), then concave (above the 45° line). Moreover, the boxplot indicates the existence of a few outliers, as shown in Figure 7.
The MLEs and the GoF statistics, along with corresponding p-values of the application described in Section 7.4, are reported in Table 15. The negative logarithm and information criteria are given in Table 16. The results reveal that the proposed model possesses the minimum values of A*, W* and K-S, along with the maximum p-value. This verifies that it yields a better fit to the COVID-19 mortality data than other models that were tested in this study.

7.5. Application 5: Failure Time of Censored Lifetime Data

The fifth application, presented in the Appendix A, involves a dataset of 30 items tested under a Type-II censoring scheme, where the test is terminated after the 20 th failure. This dataset was previously utilized by [21,22].
Table 17 reports the summary statistics of the failure time of censored lifetime data. The dataset is almost symmetric, with skewness = 0.0025 and a kurtosis value of less than 3, which implies that it is platykurtic. The failure rate is of a bathtub shape, since the TTT-transform plot is first convex (below the 45° line), then concave (above the 45° line). Moreover, the boxplot indicates the existence of a few outliers, as shown in Figure 8.
The maximum likelihood estimates (MLEs) and goodness-of-fit (GoF) statistics, along with their corresponding p-values for the application described in Section 7.5, are presented in Table 18. The negative log-likelihood and associated information criteria are summarized in Table 19. The results demonstrate that the proposed model achieves the lowest values for the A*, W* and K–S test statistics, accompanied by the highest p-value among all the competing models. These findings confirm that the proposed model provides a superior fit to the failure time of censored lifetime data compared to the alternative models considered in this study.

8. Concluding Remarks

This work advances statistical modeling through the development of the AAP-X family, a novel class of continuous distributions designed to address the inflexibility of classical models. Focusing on its exponential subclass, termed the AAPEx model, we resolve critical limitations of the traditional exponential distribution—most notably, its constant hazard rate—by introducing a shape parameter that enables more flexible hazard function modeling. The AAPEx framework supports increasing, decreasing and bathtub-shaped hazard rates, making it well-suited for complex real-world phenomena.
To lay the theoretical groundwork for the AAPEx model, we derived its structural properties, including moments, quantile functions and hazard-rate behavior. Through extensive Monte Carlo simulations, six frequentist estimation approaches (MLE, CVME, MPSE, OLSE, WLSE and ADE) were systematically implemented and compared. Practical applicability was demonstrated through four real-world datasets, including survival times of cancer patients and COVID-19 mortality rates. In all cases, the AAPEx model provided a superior fit compared to several established competing distributions, as measured by standard goodness-of-fit metrics.
This study is based on the following key assumptions: (i) the data are assumed to be independent and identically distributed (i.i.d.); (ii) the model employs a parametric form for the baseline distribution, such as the exponential; and (iii) the shape parameter ( γ ) is well-defined and governs the distribution’s flexibility. Despite its strengths, the model may face convergence issues with small samples and computational challenges with large datasets, particularly in parameter estimation.
Future research can focus on several promising directions. These include extending the AAP-X model to incorporate survival regression structures for enhanced time-to-event analysis, developing multivariate and time-dependent versions and exploring Bayesian estimation methods to improve flexibility and quantify uncertainty. Furthermore, integrating machine learning techniques could significantly enhance the efficiency and scalability of the model, especially in high-dimensional data settings.

Author Contributions

Conceptualization, A.A.M.; Methodology, A.A.M.; Software, A.A.B. and Y.S.R.; Formal analysis, A.A.B. and B.S.A.; Investigation, S.P.A. and Y.S.R.; Resources, B.S.A. and A.A.; Data curation, A.A.B.; Writing—original draft, A.A.M. and A.A.B.; Writing—review & editing, A.A.B., S.P.A. and Y.S.R.; Visualization, B.S.A. and A.A.; Supervision, S.P.A.; Project administration, B.S.A.; Funding acquisition, B.S.A. and A.A. All authors have read and agreed to the published version of the manuscript.

Funding

The research was funded by the Deanship of Graduate Studies and Scientific Research at Qassim University for financial support (QU-APC-2025).

Data Availability Statement

The data supporting the findings of this study are available within the article.

Acknowledgments

The researchers would like to thank the Deanship of Graduate Studies and Scientific Research at Qassim University for financial support (QU-APC-2025).

Conflicts of Interest

The authors declare no conflicts of interest.

Appendix A

The datasets listed below were analyzed in the section on applications in medical research.
  • Application I: Survival Time of 44 Head and Neck Cancer Patients:
1.220, 2.356, 2.374, 2.587, 3.198, 3.700, 4.135, 4.300, 4.738, 5.546, 5.836, 6.347, 6.846, 7.447, 7.826, 8.100, 8.400, 9.200, 9.400, 11.00, 11.20, 11.90, 12.70, 13.00, 13.30, 14.00, 14.60, 15.50, 15.90, 17.30, 17.90, 19.40, 19.50, 20.90, 24.90, 28.10, 31.90, 33.90, 43.20, 46.90, 51.90, 63.30, 72.50, 81.70, 177.60
  • Application II: Remission Times of 36 Bladder Cancer Patients:
0.08, 0.20, 0.40, 0.50, 0.51, 0.81, 0.87, 0.90, 1.05, 1.19, 1.26, 1.35, 1.40, 1.46, 1.76, 2.02, 2.02, 2.07, 2.09, 2.23, 2.26, 2.46, 2.54, 2.62, 2.64, 2.69, 2.69, 2.75, 2.83, 2.87, 3.02, 3.02, 3.25, 3.31, 3.36, 3.36
  • Application III: Remission Times of 128 Bladder Cancer Patients:
0.08, 2.09, 3.48, 4.87, 6.94, 8.66, 13.11, 23.63, 0.20, 2.23, 3.52, 4.98, 6.97, 9.02, 13.29, 0.40, 2.26, 3.57, 5.06, 7.09, 9.22, 13.80, 25.74, 0.50, 2.46, 3.64, 5.09, 7.26, 9.47, 14.24, 25.82, 0.51, 2.54, 3.70, 5.17, 7.28, 9.74, 14.76, 26.31, 0.81, 2.62, 3.82, 5.32, 7.32, 10.06, 14.77, 32.15, 2.64, 3.88, 5.32, 7.39, 10.34, 14.83, 34.26, 0.90, 2.69, 4.18, 5.34, 7.59, 10.66, 15.96, 36.66, 1.05, 2.69, 4.23, 5.41, 7.62, 10.75, 16.62, 43.01, 1.19, 2.75, 4.26, 5.41, 7.63, 17.12, 46.12, 1.26, 2.83, 4.33, 5.49, 7.66, 11.25, 17.14, 79.05, 1.35, 2.87, 5.62, 7.87, 11.64, 17.36, 1.40, 3.02, 4.34, 5.71, 7.93, 11.79, 18.10, 1.46, 4.40, 5.85, 8.26, 11.98, 19.13, 1.76, 3.25, 4.50, 6.25, 8.37, 12.02, 2.02, 3.31, 4.51, 6.54, 8.53, 12.03, 20.28, 2.02, 3.36, 6.76, 12.07, 21.73, 2.07, 3.36, 6.93, 8.65, 12.63, 22.69
  • Application IV: United Kingdom COVID-19 Mortality Rate Data:
0.0587, 0.0863, 0.1165, 0.1247, 0.1277, 0.1303, 0.1652, 0.2079, 0.2395, 0.2845, 0.2992, 0.3188, 0.3317, 0.3446, 0.3553, 0.3622, 0.3926, 0.3926, 0.4633, 0.4690, 0.4954, 0.5139, 0.5696, 0.5837, 0.6197, 0.6365, 0.7096, 0.7444, 0.8590, 1.0438, 1.0602, 1.1305, 1.1468, 1.1533, 1.2260, 1.2707, 1.4149, 1.5709, 1.6017, 1.6083, 1.6324, 1.6998, 1.8164, 1.8392, 1.8721, 2.1360, 2.3987, 2.4153, 2.5225, 2.7087, 2.7946, 3.3609, 3.3715, 3.7840, 4.1969, 4.3451, 4.4627, 4.6477, 5.3664, 5.4500, 5.7522, 6.4241, 7.0657, 8.2307, 9.6315, 10.1870, 11.1429, 11.2019, 11.4584, 0.2751, 0.4110, 0.7193, 1.3423, 1.9844, 3.9042, 7.4456.
  • Application V: Failure Time of Censored Lifetime Data:
0.0014, 0.0623, 1.3826, 2.0130, 2.5274, 2.8221, 3.1544, 4.9835, 5.5462, 5.8196, 5.8714, 7.4710, 7.5080, 7.6667, 8.6122, 9.0442, 9.1153, 9.6477, 10.1547, 10.7582.

References

  1. Mudholkar, G.S.; Srivastava, D.K. Exponentiated Weibull family for analyzing bathtub failure-rate data. IEEE Trans. Reliab. 1993, 42, 299–302. [Google Scholar] [CrossRef]
  2. Marshall, A.W.; Olkin, I. A new method for adding a parameter to a family of distributions with application to the exponential and Weibull families. Biometrika 1997, 84, 641–652. [Google Scholar] [CrossRef]
  3. Mahdavi, A.; Kundu, D. A new method for generating distributions with an application to exponential distribution. Commun. Stat.-Theory Methods 2017, 46, 6543–6557. [Google Scholar] [CrossRef]
  4. Lone, M.A.; Dar, I.H.; Jan, T. A new family of generalized distributions with an application to weibull distribution. Thail. Stat. 2024, 22, 1–16. [Google Scholar]
  5. Shah, Z.; Khan, D.M.; Khan, I.; Ahmad, B.; Jeridi, M.; Al-Marzouki, S. A novel flexible exponent power-X family of distributions with applications to COVID-19 mortality rate in Mexico and Canada. Sci. Rep. 2024, 14, 8992. [Google Scholar] [CrossRef] [PubMed]
  6. Alzaatreh, A.; Lee, C.; Famoye, F. A new method for generating families of continuous distributions. Metron 2013, 71, 63–79. [Google Scholar] [CrossRef]
  7. Musekwa, R.R.; Gabaitiri, L.; Makubate, B. A New Technique to Generate Families of Continuous Distributions. Colomb. J. Stat. Colomb. Estad. 2024, 47, 329–354. [Google Scholar] [CrossRef]
  8. Alsolmi, M.M. A New Logarithmic Tangent-U Family of Distributions with Reliability Analysis in Engineering Data. Comput. J. Math. Stat. Sci. 2025, 4, 258–282. [Google Scholar] [CrossRef]
  9. Odhah, O.H.; Alshanbari, H.M.; Ahmad, Z.; Khan, F.; El-Bagoury, A.a.A.H. A New Family of Distributions Using a Trigonometric Function: Properties and Applications in the Healthcare Sector. Heliyon 2024, 10, e29861. [Google Scholar] [CrossRef] [PubMed]
  10. Mir, A.A.; Rasool, S.U.; Ahmad, S.; Bhat, A.; Jawa, T.M.; Sayed-Ahmed, N.; Tolba, A.H. A Robust Framework for Probability Distribution Generation: Analyzing Structural Properties and Applications in Engineering and Medicine. Axioms 2025, 14, 281. [Google Scholar] [CrossRef]
  11. Semary, H.; Hussain, Z.; Hamdi, W.A.; Aldahlan, M.A.; Elbatal, I.; Nagarjuna, V.B. Alpha–beta-power family of distributions with applications to exponential distribution. Alex. Eng. J. 2024, 100, 15–31. [Google Scholar] [CrossRef]
  12. Balakrishnan, K. Exponential Distribution: Theory, Methods and Applications; CRC Press: Boca Raton, FL, USA, 1996. [Google Scholar]
  13. Gupta, R.D.; Kundu, D. Exponentiated exponential family: An alternative to gamma and Weibull distributions. Biom. J. J. Math. Methods Biosci. 2001, 43, 117–130. [Google Scholar] [CrossRef]
  14. Isa, A.M.; Bashiru, S.O.; Ali, B.A.; Adepoju, A.A.; Itopa, I.I. Sine-exponential distribution: Its mathematical properties and application to real dataset. UMYU Sci. 2022, 1, 127–131. [Google Scholar]
  15. Nassar, M.; Afify, A.Z.; Shakhatreh, M. Estimation methods of alpha power exponential distribution with applications to engineering and medical data. Pak. J. Stat. Oper. Res. 2020, 16, 149–166. [Google Scholar] [CrossRef]
  16. Adepoju, K.; Chukwu, O. Maximum likelihood estimation of the Kumaraswamy exponential distribution with applications. J. Mod. Appl. Stat. Methods 2015, 14, 18. [Google Scholar] [CrossRef]
  17. Sule, I.; Doguwa, S.I.; Isah, A.; Jibril, H.M. The topp leone kumaraswamy-g family of distributions with applications to cancer disease data. J. Biostat. Epidemiol. 2020, 6, 40–51. [Google Scholar] [CrossRef]
  18. Abo-Kasem, O.; Ibrahim, O.; Aljohani, H.M.; Hussam, E.; Kilai, M.; Aldallal, R. Statistical Analysis Based on Progressive Type-I Censored Scheme From Alpha Power Exponential Distribution With Engineering and Medical Applications. J. Math. 2022, 2022, 3175820. [Google Scholar] [CrossRef]
  19. Hibatullah, R.; Widyaningsih, Y.; Abdullah, S. Marshall-Olkin extended power Lindley distribution with application. J. Ris. Apl. Mat. 2018, 2, 84–92. [Google Scholar] [CrossRef]
  20. Lee, E.T.; Wang, J. Statistical Methods for Survival Data Analysis; John Wiley & Sons: Hoboken, NJ, USA, 2003; Volume 476. [Google Scholar]
  21. Kilai, M.; Waititu, G.A.; Kibira, W.A.; Alshanbari, H.M.; El-Morshedy, M. A new generalization of Gull Alpha Power Family of distributions with application to modeling COVID-19 mortality rates. Results Phys. 2022, 36, 105339. [Google Scholar] [CrossRef] [PubMed]
  22. Kargbo, M.; Gichuhi, A.W.; Wanjoya, A.K. A novel extended inverse-exponential distribution and its application to COVID-19 data. Eng. Rep. 2024, 6, e12828. [Google Scholar] [CrossRef]
Figure 1. Flowchart of the study.
Figure 1. Flowchart of the study.
Symmetry 17 00863 g001
Figure 2. PDF curves of the AAPEx model for different parameter settings of α , γ and η .
Figure 2. PDF curves of the AAPEx model for different parameter settings of α , γ and η .
Symmetry 17 00863 g002
Figure 3. Diverse hazard-rate shapes of the AAPEx model for different settings of α , γ and η .
Figure 3. Diverse hazard-rate shapes of the AAPEx model for different settings of α , γ and η .
Symmetry 17 00863 g003
Figure 4. Comparative plots evaluating the adequacy of the AAPEx model on survival times for the data of 45 head and neck cancer patients.
Figure 4. Comparative plots evaluating the adequacy of the AAPEx model on survival times for the data of 45 head and neck cancer patients.
Symmetry 17 00863 g004
Figure 5. Comparative plots for evaluation of the adequacy of the AAPEx model on remission times for the data of 36 bladder cancer patients.
Figure 5. Comparative plots for evaluation of the adequacy of the AAPEx model on remission times for the data of 36 bladder cancer patients.
Symmetry 17 00863 g005
Figure 6. Comparative plots for evaluation of the adequacy of the AAPEx model on remission times for the data of 128 bladder cancer patients.
Figure 6. Comparative plots for evaluation of the adequacy of the AAPEx model on remission times for the data of 128 bladder cancer patients.
Symmetry 17 00863 g006
Figure 7. Visual evaluation of the AAPEx model fitted to mortality rates of 76 UK COVID-19 patients.
Figure 7. Visual evaluation of the AAPEx model fitted to mortality rates of 76 UK COVID-19 patients.
Symmetry 17 00863 g007
Figure 8. Visual evaluation of the AAPEx model fitted to mortality rates of 76 UK COVID-19 patients.
Figure 8. Visual evaluation of the AAPEx model fitted to mortality rates of 76 UK COVID-19 patients.
Symmetry 17 00863 g008
Table 1. Quantiles, Bowley skewness and Moor’s kurtosis for the AAPEx model under varying parameters.
Table 1. Quantiles, Bowley skewness and Moor’s kurtosis for the AAPEx model under varying parameters.
λ η α = 0.25 α = 0.75
Q 1 Q 2 Q 3 BSK MKUR Q 1 Q 2 Q 3 BSK MKUR
0.251.20.09390.43911.07890.29910.77590.00750.09390.43910.59941.5439
1.70.06630.31000.76160.00530.06630.3100
2.10.05370.25090.61650.00430.05370.2509
2.50.04510.21080.51790.00360.04510.2108
1.251.20.84931.50922.31680.10070.29290.41120.84931.50920.20200.5413
1.70.59951.06531.63540.29030.59951.0653
2.10.48530.86241.32390.23500.48530.8624
2.50.40770.72441.11210.19740.40770.7244
2.251.21.26101.96672.79490.07990.23510.74761.26101.96670.15770.4276
1.70.89011.38831.97290.52770.89011.3883
2.10.72061.12381.59710.42720.72061.1238
2.50.60530.94401.34150.35880.60530.9440
Table 2. Simulation-based performance of estimators with α = 0.25 , γ = 0.15 and η = 0.35 .
Table 2. Simulation-based performance of estimators with α = 0.25 , γ = 0.15 and η = 0.35 .
MetricParamSample Size Δ 1 Δ 2 Δ 3 Δ 4 Δ 5 Δ 6
AB α 250.30500.57100.32400.52400.35700.2640
500.17500.33400.21000.31100.17700.1930
1000.14500.21100.10600.18200.13500.1420
1500.08700.12200.09000.12700.13300.0880
2500.08000.09900.06400.09900.07700.0910
4000.04800.08000.05000.08300.06600.0630
γ 250.24700.48900.33700.45700.31500.2520
500.14400.24300.21300.27800.18900.1440
1000.11800.19500.12400.16800.13500.1090
1500.09200.13400.10600.12400.11800.0930
2500.06100.09900.07200.09700.09600.0720
4000.04800.06400.05200.07000.07100.0510
η 250.25000.51500.30300.47400.32700.2760
500.16800.31400.18700.29200.19100.1790
1000.13700.20500.13000.17800.13800.1350
1500.08400.13100.09600.12700.11400.0950
2500.07300.09200.07200.09700.08300.0840
4000.05900.08200.06200.08600.07300.0620
MSE α 250.14730.45660.15460.36180.18180.0934
500.03830.12670.04620.11250.04430.0410
1000.02030.04450.01400.03410.02060.0202
1500.00760.01740.00860.01820.02160.0083
2500.00630.00980.00460.01040.00640.0079
4000.00250.00660.00250.00700.00430.0040
γ 250.09940.34920.15020.28150.12890.0877
500.03000.07400.04560.07470.03630.0242
1000.01650.03820.01960.02880.02030.0143
1500.00930.01930.01250.01710.01540.0094
2500.00470.00970.00620.00940.00910.0063
4000.00260.00460.00300.00510.00510.0029
η 250.10520.37360.13840.31050.14780.1012
500.03220.10340.03610.08860.03530.0315
1000.01870.04190.01620.03220.01900.0182
1500.00700.02130.01010.01960.01320.0095
2500.00540.01000.00570.01080.00700.0066
4000.00350.00730.00400.00820.00500.0040
MRE α 251.22002.28401.29602.09601.42801.0560
500.70001.33600.84001.24400.70800.7720
1000.58000.84400.42400.72800.54000.5680
1500.34800.48800.36000.50800.53200.3520
2500.32000.39600.25600.39600.30800.3640
4000.19200.32000.20000.33200.26400.2520
γ 251.64703.26002.24703.04702.10001.6800
500.96001.62001.42001.85301.26000.9600
1000.78601.30000.82601.12000.90000.7260
1500.61400.89300.70400.82700.78700.6200
2500.40700.66000.48000.64700.64000.4800
4000.32000.42700.34700.46700.47300.3400
η 250.71401.47100.86601.35300.93400.7880
500.48000.94200.56100.83300.54600.5110
1000.39200.58600.37000.50700.39400.3850
1500.24000.37400.27400.36200.32500.2700
2500.20800.26200.20800.27600.23600.2400
4000.16800.23400.17600.24600.21400.1780
Table 3. Simulation-based performance of estimators with α = 0.7 , γ = 2.0 and η = 0.8 .
Table 3. Simulation-based performance of estimators with α = 0.7 , γ = 2.0 and η = 0.8 .
MetricParamSample Size Δ 1 Δ 2 Δ 3 Δ 4 Δ 5 Δ 6
AB α 250.79321.09420.90511.12670.89740.8062
500.56070.83260.68760.84750.62120.6387
1000.47960.72060.53910.56690.50310.5695
1500.31620.41710.40280.48520.41970.2948
2500.28610.34200.26090.32950.27100.3203
4000.17780.28840.21860.27210.23970.2141
γ 250.77111.04900.87400.82380.87340.7766
500.52780.70980.64590.65560.59380.5636
1000.44920.53910.41090.60170.39580.4083
1500.31080.41580.32970.39220.38560.3523
2500.23150.33930.26040.33810.26150.3168
4000.19600.25730.16830.29390.21260.2464
η 250.23330.30760.23040.28200.24050.2404
500.16670.20260.17400.22620.20210.1884
1000.11510.17190.13690.16340.15130.1425
1500.08540.11300.11100.13410.10300.1056
2500.08320.09970.07720.09360.08050.0872
4000.06170.08600.06910.08060.07590.0668
MSE α 251.17901.88091.43912.03801.41981.2121
500.68711.35940.93351.34500.78170.8637
1000.50681.05830.59810.67890.56500.6949
1500.21690.41920.38670.49630.44350.1587
2500.20750.24620.13700.20290.15820.1758
4000.05530.16740.08150.13010.09350.0787
γ 250.95381.66081.22251.11301.11510.9672
500.51980.84790.65150.68830.57570.5274
1000.33790.51240.27000.55170.25560.2822
1500.14160.27720.16790.25650.23560.2088
2500.09060.17510.10220.17090.10790.1403
4000.06080.10550.04350.12500.07090.0847
η 250.09420.15490.08640.12480.08450.0949
500.04470.06620.04620.07430.07080.0548
1000.02130.04320.02750.03970.03390.0289
1500.01220.01980.01900.02750.01770.0178
2500.01150.01550.01000.01430.00950.0118
4000.00590.01110.00720.01020.00810.0066
MRE α 251.13321.56311.29311.60961.28201.1517
500.80101.18940.98231.21060.88740.9124
1000.68521.02950.77010.80990.71870.8136
1500.45170.59580.57540.69320.59960.4212
2500.40880.48850.37270.47070.38720.4576
4000.25400.41200.31220.38870.34250.3059
γ 250.38560.52450.43700.41190.43670.3883
500.26390.35490.32300.32780.29690.2818
1000.22460.26960.20550.30080.19790.2041
1500.15540.20790.16490.19610.19280.1761
2500.11580.16970.13020.16910.13080.1584
4000.09800.12870.08420.14690.10630.1232
η 250.29160.38450.28800.35250.30060.3005
500.20830.25330.21750.28280.25260.2354
1000.14380.21480.17110.20430.18920.1782
1500.10680.14120.13870.16760.12870.1320
2500.10400.12460.09650.11700.10060.1090
4000.07710.10750.08640.10070.09490.0835
Table 4. Simulation-based performance of estimators with α = 1.2 , γ = 0.7 and η = 2.1 .
Table 4. Simulation-based performance of estimators with α = 1.2 , γ = 0.7 and η = 2.1 .
MetricParamSample Size Δ 1 Δ 2 Δ 3 Δ 4 Δ 5 Δ 6
AB α 250.90531.11940.99501.07870.96990.8623
500.64430.86260.76960.87600.70150.7216
1000.60370.76050.62560.68570.60300.6525
1500.44220.52810.49600.57610.54400.4161
2500.36390.44760.35390.46500.34310.4373
4000.24650.38440.28060.38000.31470.3066
γ 250.22340.28900.26790.22490.24850.2175
500.14580.18730.18640.18370.16580.1560
1000.13110.15390.12170.17180.11540.1200
1500.09480.12240.09840.11240.11190.1054
2500.07050.09760.08030.09800.07570.0925
4000.05850.07460.05260.08580.06420.0744
η 250.81721.04340.76650.88600.84510.8225
500.57910.69990.55730.77750.69080.6248
1000.39300.57500.42700.57920.50980.4591
1500.28920.38290.35710.45330.33590.3579
2500.27260.35130.25680.33030.25870.2997
4000.20200.30170.22010.27930.25010.2321
MSE α 251.18001.57891.32321.54161.24991.0802
500.67361.10300.90871.14160.75600.8268
1000.61970.96020.63880.76200.62220.7678
1500.34240.50120.44550.55140.55040.3027
2500.28110.34690.21520.37270.22160.2948
4000.09730.27960.12490.22810.15600.1540
γ 250.08270.14650.11940.09650.09070.0720
500.03600.05700.05270.05300.04260.0394
1000.02780.03840.02290.04280.02120.0237
1500.01320.02310.01470.02120.01980.0182
2500.00820.01450.00950.01430.00910.0119
4000.00530.00900.00400.01050.00650.0076
η 251.20831.89531.05011.26231.15301.1465
500.56380.86140.50941.03230.93520.6747
1000.25650.53440.27210.56300.40280.3098
1500.14180.23660.18580.31540.18840.2029
2500.12060.19170.10770.17790.10210.1427
4000.06320.13570.07280.12380.09260.0836
MRE α 250.75440.93280.82920.89890.80830.7186
500.53690.71880.64130.73000.58460.6014
1000.50310.63380.52130.57140.50250.5437
1500.36850.44010.41330.48010.45330.3467
2500.30320.37300.29490.38750.28590.3644
4000.20540.32030.23380.31670.26220.2555
γ 250.31920.41290.38270.32130.35500.3107
500.20830.26760.26620.26240.23680.2228
1000.18730.21990.17390.24540.16480.1714
1500.13540.17480.14050.16050.15980.1505
2500.10070.13940.11470.14000.10810.1322
4000.08360.10650.07510.12260.09170.1062
η 250.38910.49680.36500.42190.40240.3916
500.27570.33330.26540.37030.32890.2975
1000.18710.27380.20330.27580.24280.2186
1500.13770.18230.17000.21580.16000.1704
2500.12980.16730.12230.15730.12320.1427
4000.09620.14370.10480.13300.11910.1105
Table 5. Summary statistics of 45 patients diagnosed with head and neck cancer disease.
Table 5. Summary statistics of 45 patients diagnosed with head and neck cancer disease.
NMinMaxMeanMedianSDCVSkewnessKurtosis
451.22177.6019.5813.0027.331.392.608.43
Table 6. MLEs With GoF statistics for 45 patients with head and neck cancer disease.
Table 6. MLEs With GoF statistics for 45 patients with head and neck cancer disease.
Model α ^ γ ^ η ^ A * W * KSp-Value
AAPEx22.645021.749710.014770.118540.013290.048230.99978
Ex0.045571.025060.187370.144580.27615
EEx0.047401.060551.084720.206490.148310.24971
W0.9348521.138570.908810.146100.128940.40838
SEx0.025361.292980.251480.158130.18911
G1.013820.046201.040620.192500.145800.26730
APEx0.009850.012890.696470.094080.108120.62967
KwEx1.351570.341430.144641.309920.265390.154900.20763
MoEx0.478280.030000.870130.127450.110550.60213
Table 7. The negative logarithm and the information criteria results for 45 patients with head and neck cancer disease.
Table 7. The negative logarithm and the information criteria results for 45 patients with head and neck cancer disease.
Model AICSICAICCHQIC
AAPEx179.2323364.4645369.8845373.2450366.4850
Ex183.9857369.9714371.7780374.1574370.6449
EEx183.9450371.8899375.5032378.3185373.2369
W183.7745371.5489375.1623377.9775372.8960
SEx184.7475371.4951373.3017375.6811372.1686
G183.9830371.9659375.5793378.3945373.3129
APEx182.1599368.3198371.9332374.7484369.6668
KwEx183.5517373.1034378.5234381.8839375.1239
MoEx182.9520369.9040373.5173376.3325371.2510
Table 8. Summary statistics of 36 patients diagnosed with bladder cancer disease.
Table 8. Summary statistics of 36 patients diagnosed with bladder cancer disease.
NMinMaxMeanMedianSDCVSkewnessKurtosis
360.083.361.942.080.990.51−0.301.86
Table 9. MLEs With GoF statistics for 36 patients with bladder cancer disease.
Table 9. MLEs With GoF statistics for 36 patients with bladder cancer disease.
Model α ^ γ ^ η ^ A * W * KSp-Value
AAPEx0.035810.656531.515560.717980.105160.111530.76174
Ex0.515463.408310.655560.230320.04388
EEx0.812372.272351.482940.256930.196280.12482
W1.956982.164481.106040.174720.165870.27522
SEx0.292133.075620.589290.227670.04789
G2.309641.190531.406280.241060.194450.13137
APEx57.94661.011151.031850.167950.166790.26915
KwEx1.95798100.0050.013791.112890.177450.168120.26076
MoEx17.16671.493800.766850.109650.114380.73394
Table 10. The negative logarithm and the information criteria results for 36 patients with bladder cancer.
Table 10. The negative logarithm and the information criteria results for 36 patients with bladder cancer.
Model AICSICAICCHQIC
AAPEx50.16594106.3319111.0824115.3319107.9901
Ex59.85677121.7135123.2971125.9488122.2662
EEx54.82474113.6495116.8165120.1949114.7549
W51.38705106.7741109.9411113.3195107.8795
SEx58.48822118.9764120.5599123.2117119.5291
G54.09240112.1848115.3518118.7303113.2903
APEx52.58815109.1763112.3433115.7217110.2817
KwEx51.51497109.0299113.7805118.0299110.6880
MoEx54.24223108.4845112.6515116.0299109.5898
Table 11. Summary statistics of 128 patients diagnosed with bladder cancer.
Table 11. Summary statistics of 128 patients diagnosed with bladder cancer.
NMinMaxMeanMedianSDCVSkewnessKurtosis
1280.0879.059.376.4010.511.123.3216.15
Table 12. MLEs With GoF statistics for 128 patients with bladder cancer.
Table 12. MLEs With GoF statistics for 128 patients with bladder cancer.
Model α ^ γ ^ η ^ A * W * KSp-Value
AAPEx4.537311.651110.0708195.558616.451830.035080.99749
Ex0.1067798.0829917.205770.084630.31835
EEx0.121171.21795108.766218.265170.072510.51132
W1.047849.56069102.443917.603500.070020.55696
SEx0.05974103.437517.674660.071300.53327
G1.172510.12519107.271318.101900.073290.49738
APEx1.173890.1113299.8177417.353120.079340.39612
KwEx1.392310.368870.31797109.669718.411340.071310.53309
MoEx1.055800.1098699.2321217.302570.081130.36848
Table 13. The negative logarithm and the information criteria results for 128 patients with bladder cancer.
Table 13. The negative logarithm and the information criteria results for 128 patients with bladder cancer.
Model AICSICAICCHQIC
AAPEx409.3431824.6862832.2422832.9442828.1625
Ex414.3419830.6838833.5358834.7473831.8426
EEx413.0776830.1552835.8592836.2992832.4728
W414.0869832.1738837.8778838.3178834.4913
SEx414.3326830.6652833.5172834.7287831.8240
G413.3678830.7356836.4396836.8796833.0531
APEx414.3182832.6364838.3404838.7804834.9540
KwEx412.5467831.0934839.6495839.3515834.5698
MoEx414.3262832.6523838.3564838.7963834.9699
Table 14. Summary statistics of United Kingdom COVID-19 mortality rate data.
Table 14. Summary statistics of United Kingdom COVID-19 mortality rate data.
NMinMaxMeanMedianSDCVSkewnessKurtosis
760.058711.45842.441.252.941.201.732.32
Table 15. MLEs with GoF statistics for United Kingdom COVID-19 mortality rate data.
Table 15. MLEs with GoF statistics for United Kingdom COVID-19 mortality rate data.
Model α ^ γ ^ η ^ A * W * KSp-Value
AAPEx4.188141.147960.2172911.568242.088060.062010.93198
Ex0.4103115.180112.558090.144690.08295
EEx0.353030.8009412.369362.172380.098540.45159
W0.846592.2200111.687622.078680.080550.70739
SEx0.2250416.913112.794310.167980.02743
G0.803740.3297812.277182.158860.096150.48331
APEx0.152080.2540312.048562.135960.081090.69971
KwEx0.84519162.0770.0010811.693602.079780.080940.70182
MoEx0.361650.2400411.696792.103250.071290.90182
Table 16. The negative logarithm and the information criteria results for United Kingdom COVID-19 mortality rate data.
Table 16. The negative logarithm and the information criteria results for United Kingdom COVID-19 mortality rate data.
Model AICSICAICCHQIC
AAPEx139.9784285.9568292.9490294.4013288.7513
Ex143.7044289.4088291.7395293.5169290.3402
EEx142.5029289.0059293.6673295.2524290.8688
W141.7519287.5037292.1652293.7503289.3667
SEx145.6999293.3997295.7305297.5079294.3312
G142.4105288.8209293.4824295.0675290.6839
APEx140.8746285.7492290.4107291.9958287.6122
KwEx141.7632289.5265296.5187297.9709292.3209
MoEx141.3077286.6154293.5187295.9709289.3209
Table 17. Summary statistics of failure time of censored lifetime data.
Table 17. Summary statistics of failure time of censored lifetime data.
NMinMaxMeanMedianSDCVSkewnessKurtosis
200.001410.75825.425.363.440.630.00251.87
Table 18. MLEs with GoF statistics for failure time of censored lifetime data.
Table 18. MLEs with GoF statistics for failure time of censored lifetime data.
Model α ^ γ ^ η ^ A * W * KSp-Value
AAPEx0.008430.083420.415870.481250.061640.137950.79243
Ex0.175191.701890.267030.232310.19687
EEx0.157010.837731.881510.335510.249320.13961
W1.089265.816391.597420.227060.220470.24651
SEx0.098361.565460.234130.221780.24059
G0.863690.151301.844260.322410.246030.14952
APEx12.407030.281991.131440.108650.163040.60540
KwEx0.307180.059882.742891.590800.307640.239030.17242
MoEx8.086090.398421.052470.078250.147230.72520
Table 19. The negative logarithm and the information criteria results for failure time of censored lifetime data.
Table 19. The negative logarithm and the information criteria results for failure time of censored lifetime data.
Model AICSICAICCHQIC
AAPEx48.1684102.3368105.3239112.3368102.9199
Ex54.8377111.6754112.6711116.1199111.8698
EEx54.6205113.2411115.2325120.2999113.6298
W54.7518113.5036115.4950120.5624113.8923
SEx54.2871110.5741111.5699115.0186110.7685
W54.6896113.3792115.3707120.4380113.7679
APEx52.9431109.8862111.8777116.9450110.2750
KwEx52.5538111.1076114.0948121.1076111.6907
MoEx51.8900107.7801109.7715114.8389108.1688
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Mir, A.A.; Bhat, A.A.; Ahmad, S.P.; Alnssyan, B.S.; Alsubie, A.; Raghav, Y.S. Statistical Inference and Goodness-of-Fit Assessment Using the AAP-X Probability Framework with Symmetric and Asymmetric Properties: Applications to Medical and Reliability Data. Symmetry 2025, 17, 863. https://doi.org/10.3390/sym17060863

AMA Style

Mir AA, Bhat AA, Ahmad SP, Alnssyan BS, Alsubie A, Raghav YS. Statistical Inference and Goodness-of-Fit Assessment Using the AAP-X Probability Framework with Symmetric and Asymmetric Properties: Applications to Medical and Reliability Data. Symmetry. 2025; 17(6):863. https://doi.org/10.3390/sym17060863

Chicago/Turabian Style

Mir, Aadil Ahmad, A. A. Bhat, S. P. Ahmad, Badr S. Alnssyan, Abdelaziz Alsubie, and Yashpal Singh Raghav. 2025. "Statistical Inference and Goodness-of-Fit Assessment Using the AAP-X Probability Framework with Symmetric and Asymmetric Properties: Applications to Medical and Reliability Data" Symmetry 17, no. 6: 863. https://doi.org/10.3390/sym17060863

APA Style

Mir, A. A., Bhat, A. A., Ahmad, S. P., Alnssyan, B. S., Alsubie, A., & Raghav, Y. S. (2025). Statistical Inference and Goodness-of-Fit Assessment Using the AAP-X Probability Framework with Symmetric and Asymmetric Properties: Applications to Medical and Reliability Data. Symmetry, 17(6), 863. https://doi.org/10.3390/sym17060863

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop